Flulaval Post Vaccination

FLULAVAL QUADRIVALENT was studied in a randomized, observer-blind, active, comparator-controlled immunogenicity and safety trial. The trial included subjects aged 6 through 35 months who received FLULAVAL QUADRIVALENT 0.5 mL (n=1207) or Fluzone Quadrivalent 0.25 mL (n=1217). Immune responses were evaluated in sera obtained 28 days following 1 or 2 doses, depending on vaccination history, of FLULAVAL QUADRIVALENT or the comparator.¹